Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial to Evaluate the Efficacy of WSD0922-FU When Combined With Adjuvant Temozolomide in Patients With EGFR Mutant Glioblastoma

NCT07708961 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07708961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07708961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial to Evaluate the Efficacy of WSD0922-FU When Combined With Adjuvant Temozolomide in Patients With EGFR Mutant Glioblastoma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Suspended
Start date
August 28, 2026
Completion date
August 31, 2036
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, idh-wildtype